Literature DB >> 1607190

Bullous impetigo in homosexual men--a risk marker for HIV-1 infection?

B Donovan1, R Rohrsheim, I Bassett, B P Mulhall.   

Abstract

OBJECTIVE: To determine the incidence of bullous impetigo in a group of homosexual men at high risk of HIV-1 infection.
DESIGN: A longitudinal descriptive study (1984-9).
SETTING: A private primary care and STD clinic in Sydney, Australia.
SUBJECTS: 88 homosexual men documented to seroconvert to HIV-1, and 37 homosexual controls who had practised unprotected anal intercourse with another man known to be HIV-1 positive but who remained HIV-1 negative. MAIN OUTCOME MEASURE: Incidence of bullous impetigo.
RESULTS: The crude annual incidence of bullous impetigo was 0.015 in subjects while they remained HIV-1 negative (10 cases) and 0.045 in early HIV-1 positive subjects (2 cases). Overall, 9% of the HIV-1 seroconverters and 9% of the HIV-1 negative controls were documented as suffering bullous impetigo over a mean of 29.2 and 39.3 months, respectively.
CONCLUSIONS: Bullous impetigo in an adult could prove to be a clinical indication that a person is either infected with HIV-1 or is in close (possibly sexual) contact with a person with HIV-1 infection. If true, the recognition of bullous impetigo could provide an opportunity for behavioural intervention to limit the spread of HIV-1.

Entities:  

Mesh:

Year:  1992        PMID: 1607190      PMCID: PMC1194846          DOI: 10.1136/sti.68.3.159

Source DB:  PubMed          Journal:  Genitourin Med        ISSN: 0266-4348


  18 in total

1.  Impaired neutrophil function in patients with AIDS or AIDS-related complex: a comprehensive evaluation.

Authors:  M Ellis; S Gupta; S Galant; S Hakim; C VandeVen; C Toy; M S Cairo
Journal:  J Infect Dis       Date:  1988-12       Impact factor: 5.226

2.  Dermatologic findings related to human immunodeficiency virus infection in high-risk individuals.

Authors:  S L Valle
Journal:  J Am Acad Dermatol       Date:  1987-12       Impact factor: 11.527

3.  Defective phagocytosis of staphylococci.

Authors:  P G Quie; H R Hill; A T Davis
Journal:  Ann N Y Acad Sci       Date:  1974-07-31       Impact factor: 5.691

4.  HIV infection in sexually transmissible disease practice in Sydney: the effects of legislation, public education and changing clinical spectrum.

Authors:  B Donovan; R J Finlayson; K Mutimer; R Price; M Robertson; M Nelson; M Slade; I Reece; J dalle Nogare
Journal:  Int J STD AIDS       Date:  1990-01       Impact factor: 1.359

5.  Early warning skin signs in AIDS and persistent generalized lymphadenopathy.

Authors:  M F Muhlemann; M G Anderson; F J Paradinas; P R Key; S G Dawson; B A Evans; I M Murray-Lyon; J J Cream
Journal:  Br J Dermatol       Date:  1986-04       Impact factor: 9.302

6.  The relationship of abnormalities of cellular immunity to antibodies to HTLV-III in homosexual men.

Authors:  B S Dobozin; F N Judson; D L Cohn; K A Penley; P E Rickmann; M J Blaser; P S Sarin; S H Weiss; C H Kirkpatrick
Journal:  Cell Immunol       Date:  1986-03       Impact factor: 4.868

7.  Epidemiological investigation of exfoliative toxin-producing Staphylococcus aureus strains in hospitalized patients.

Authors:  Y Piemont; D Rasoamananjara; J M Fouace; T Bruce
Journal:  J Clin Microbiol       Date:  1984-03       Impact factor: 5.948

8.  Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome.

Authors:  H C Lane; H Masur; L C Edgar; G Whalen; A H Rook; A S Fauci
Journal:  N Engl J Med       Date:  1983-08-25       Impact factor: 91.245

9.  Prevalence of cutaneous disease in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex.

Authors:  D S Goodman; E D Teplitz; A Wishner; R S Klein; P G Burk; E Hershenbaum
Journal:  J Am Acad Dermatol       Date:  1987-08       Impact factor: 11.527

10.  Skin disease in homosexual patients with acquired immune deficiency syndrome (AIDS) and lesser forms of human T cell leukaemia virus (HTLV III) disease.

Authors:  C F Farthing; R C Staughton; C M Rowland Payne
Journal:  Clin Exp Dermatol       Date:  1985-01       Impact factor: 3.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.